BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 21, 2003
 |  BioCentury  |  Emerging Company Profile

CareX: Co-factoring for efficacy

Many nuclear receptors are targets for diabetes and other metabolic indications, with marketed compounds validating them. But such receptors can recruit and form a complex with more than one kind of co-factor to control DNA transcription. And new research indicates that the gene activated by a nuclear receptor depends, at least in part, on which co-factor the receptor recruits.

By tweaking small molecule ligands, CareX S.A. believes it can favor the recruitment of one co-factor over another to discover and develop drugs with fewer side effects to treat diabetes, obesity and cardiovascular diseases.

Different molecules acting at the same nuclear receptors can evoke different regulatory responses, according to CEO Bernard Gilly, who is also a general partner at Sofinnova, one of CareX's backers. One such nuclear receptor, PPAR gamma, "probably regulates more than 50 genes," CSO Jurgen Lehmann noted.

CareX and others suspect this is possible because a single nuclear receptor can recruit many different kinds...

Read the full 785 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >